Leveraging circulating microbial DNA for early cancer detection.
cancer
circulating microbial DNA
early detection
liquid biopsy
microbiome
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
20
05
2023
revised:
27
07
2023
accepted:
01
08
2023
medline:
23
10
2023
pubmed:
3
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
Microbial cell-free DNA (microbial cfDNA) offers a minimally invasive approach for profiling the microbiome. Despite technical and biological challenges, the potential of microbial cfDNA for cancer detection is increasingly being evaluated using deep sequencing, novel laboratory approaches, and computational methods. Targeting the microbiome using liquid biopsies could improve early cancer detection.
Identifiants
pubmed: 37659908
pii: S2405-8033(23)00157-7
doi: 10.1016/j.trecan.2023.08.001
pii:
doi:
Substances chimiques
DNA
9007-49-2
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
879-882Subventions
Organisme : Medical Research Council
ID : ST11272
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S016899/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.C.M.W. is an inventor of patents for methods for ctDNA detection. He is a stockholder and a cofounder of cfdx. He has served as a consultant for Delfi Diagnostics and Cleary Gottlieb. The other authors declare no conflicts of interest.